Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design.
about
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesElicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoproteinHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesInfluenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protectionDesign of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge.Hemagglutinin Sequence Conservation Guided Stem Immunogen Design from Influenza A H3 SubtypeDesign of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge.NMR structural analysis of a peptide mimic of the bridging sheet of HIV-1 gp120 in methanol and water.sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates.Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses.Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogensStabilization of HIV-1 gp120-CD4 receptor complex through targeted interchain disulfide exchangeDesign of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies.Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.In Vitro Evaluation of Influenza M2 and Leishmania major HSP70 (221-604) Chimer ProteinAllosteric induction of the CD4-bound conformation of HIV-1 Gp120.Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimeticAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.Characterization of the steric defense of the HIV-1 gp41 N-trimer region.Increased, durable B-cell and ADCC Responses Associated with T-helper Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site.Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodiesCrosslinking of a CD4 Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.Role of human CD4 D1D2 domain in HIV-1 infection.Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies.Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV.Refolding and simultaneous purification by three-phase partitioning of recombinant proteins from inclusion bodies.In vitro and in vivo characterization of designed immunogens derived from the CD-helix of the stem of influenza hemagglutinin.
P2860
Q27489000-B607E4E4-462F-45DC-9762-F977C4A697CDQ28732438-DB5E7ACC-DC18-4407-8BBD-A3B357AEA56DQ29619015-E287A585-A767-40BD-BE7F-604C6E905596Q30209769-27AE26B2-91DD-4E90-B338-DFEC2A316751Q30227081-798F38AD-A8DB-44F6-A212-DD4BB82C0AD0Q30376605-159F8F34-16AB-46BE-95BB-CDD4E93D5F78Q30421687-6A754450-B2E4-4B4B-8312-DD63132E4771Q30989881-F9220C93-394F-49DD-9DC1-63A02EE914A3Q33348658-8A577AA1-9837-4692-B8EB-499D6D8FF95AQ33911809-E43F658B-C2E0-42C8-95EC-2907988E956EQ33946209-3AEC4BA4-620B-4FB7-B6F5-1664B1A6C04BQ34055984-C22CDFF7-17D7-4084-8787-DDB7EE04F938Q34094476-1613CC91-942E-4326-B303-DC1F654FFD1EQ34555891-B4AB8C0A-3FD0-4265-A501-616D58972B6AQ34629573-F58F871D-91D9-439B-99ED-2B968AC22928Q35058860-083D4F14-8BFA-4908-ACC2-5EFBB3FB46C9Q35065249-763F6A77-A134-4A5D-AE4D-09CD5922A6A4Q36600380-CAF3C639-95A4-4668-B52D-03B5E16FD6A7Q36990646-EED63DD4-8D6A-45E1-8E25-0740E6A80226Q38658529-4C75D8FB-E1F9-4ECE-B744-8A23196F230CQ38739398-5D526DEC-F068-496E-A71B-2235E2A865B9Q38793711-21115B37-A73B-4D73-8DAF-D3DA4FD7CC8DQ39223730-7A2E0B2D-0673-4176-B231-CA26F4B62560Q40438707-0D1CB317-7AA0-439D-B3D5-6E803C54EE1AQ42166543-A0279ABA-29D0-4222-89D4-02D8ACDF64A4Q43246361-AE9FE784-DDB8-48D1-BF4D-78B5E26FA392Q47893467-BA914FAF-37E8-4717-A293-91A9C8C5B2AB
P2860
Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Characterization of gp120 and ...... ficiency virus vaccine design.
@ast
Characterization of gp120 and ...... ficiency virus vaccine design.
@en
type
label
Characterization of gp120 and ...... ficiency virus vaccine design.
@ast
Characterization of gp120 and ...... ficiency virus vaccine design.
@en
prefLabel
Characterization of gp120 and ...... ficiency virus vaccine design.
@ast
Characterization of gp120 and ...... ficiency virus vaccine design.
@en
P2093
P2860
P1433
P1476
Characterization of gp120 and ...... ficiency virus vaccine design.
@en
P2093
David Bramhill
Debra Eckert
Deepak Sharma
John Shiver
Mayuri Patel
Michael Citron
Prem Sinha
Raghavan Varadarajan
Ramkishor Yadav
Romas Geleziunas
P2860
P304
P356
10.1128/JVI.79.3.1713-1723.2005
P577
2005-02-01T00:00:00Z